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Summary
Background Efforts to quantify the global burden of enteric fever are valuable for understanding the health lost and 
the large-scale spatial distribution of the disease. We present the estimates of typhoid and paratyphoid fever burden 
from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, and the approach taken to 
produce them.
Methods For this systematic analysis we broke down the relative contributions of typhoid and paratyphoid fevers by 
country, year, and age, and analysed trends in incidence and mortality. We modelled the combined incidence of 
typhoid and paratyphoid fevers and split these total cases proportionally between typhoid and paratyphoid fevers 
using aetiological proportion models. We estimated deaths using vital registration data for countries with sufficiently 
high data completeness and using a natural history approach for other locations. We also estimated disability-adjusted 
life-years (DALYs) for typhoid and paratyphoid fevers.
Findings Globally, 14·3 million (95% uncertainty interval [UI] 12·5–16·3) cases of typhoid and paratyphoid 
fevers occurred in 2017, a 44·6% (42·2–47·0) decline from 25·9 million (22·0–29·9) in 1990. Age-standardised 
incidence rates declined by 54·9% (53·4–56·5), from 439·2 (376·7–507·7) per 100 000 person-years in 1990, to 
197·8 (172·0–226·2) per 100 000 person-years in 2017. In 2017, Salmonella enterica serotype Typhi caused 
76·3% (71·8–80·5) of cases of enteric fever. We estimated a global case fatality of 0·95% (0·54–1·53) in 2017, with 
higher case fatality estimates among children and older adults, and among those living in lower-income countries. 
We therefore estimated 135·9 thousand (76·9–218·9) deaths from typhoid and paratyphoid fever globally in 2017, a 
41·0% (33·6–48·3) decline from 230·5 thousand (131·2–372·6) in 1990. Overall, typhoid and paratyphoid fevers were 
responsible for 9·8 million (5·6–15·8) DALYs in 2017, down 43·0% (35·5–50·6) from 17·2 million (9·9–27·8) DALYs 
in 1990.
Interpretation Despite notable progress, typhoid and paratyphoid fevers remain major causes of disability and death, 
with billions of people likely to be exposed to the pathogens. Although improvements in water and sanitation remain 
essential, increased vaccine use (including with typhoid conjugate vaccines that are effective in infants and young 
children and protective for longer periods) and improved data and surveillance to inform vaccine rollout are likely to 
drive the greatest improvements in the global burden of the disease.
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license.
Introduction
Typhoid and paratyphoid fevers, collectively referred 
to as enteric fever, are caused by systemic infection 
with Salmonella enterica subspecies serovars Typhi and 
Paratyphi A, B, and C.1 Whereas most non-typhoidal 
Salmonella spp infections typically produce diarrhoeal 
illness and less commonly cause bloodstream infection, 
typhoid and paratyphoid infections produce primarily 
bacteraemic febrile illnesses, with prolonged high fever, 
headache, and malaise being characteristic symptoms. 
Without effective treatment, typhoid and paratyphoid 
fevers can lead to altered mental states (termed 
the typhoid state2), ileus, gastrointestinal bleeding, 
intestinal perforation, septic shock, and death.1,3 Typhoid 
and paratyphoid infections are relatively common in 
countries with poor water supply and sanitation, 
especially south Asia, southeast Asia, and sub-Saharan 
Africa, where they are a major cause of death and 
disability, especially among children.4–7
With growing antimicrobial resistance, and intensifying 
conversations around typhoid vaccine policy, accurate 
and detailed estimates of enteric fever burden are 
required.8 The Strategic Advisory Group of Experts 
(SAGE) of WHO convened in October, 2017, and 
recommended the use of typhoid conjugate vaccines in 
children between 6 months and 2 years of age, with a 
catch-up campaign for children up to 15 years of age, 
where possible, and WHO pre qualified the first typhoid 
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conjugate vaccine in December, 2017.8 These de- 
velopments give typhoid-endemic, low-income countries 
priority access and funding for the vaccine and could 
make vaccines increasingly accessible. However, data to 
support their introduction remain sparse.9
Efforts to quantify the global burden of enteric fever 
have produced estimates ranging from 11·9 million to 
27·1 million cases per year.5–7,10,11 These estimates are 
invaluable in understanding the health lost to enteric 
fever and in clarifying the large-scale spatial distribution 
of the disease. However, none of these studies 
produced country-level estimates separately for typhoid 
and paratyphoid fevers. Moreover, most studies have 
previously assumed a uniform case fatality of 1%5,6,12 and 
none has investigated the effects of age or income on 
case fatality. Finally, most studies have developed point 
estimates rather than trends.
With each iteration of the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD),13–16 we have 
improved our estimation methods and acquired 
additional data that have allowed us to address some of 
the shortcomings of previous enteric fever estimates. 
Here, we present estimates of the typhoid and 
paratyphoid fever burden from GBD 2017, separately 
and collectively, by country, year, age, and sex. In 
addition to estimating incidence and mortality, we 
present estimates of three health gap metrics: years of 
life lost (YLLs) to premature mortality, years lived with 
dis ability (YLDs), and disability-adjusted life-years 
(DALYs).
Methods
Overview 
For this systematic analysis we modelled the combined 
incidence of typhoid and paratyphoid infections. We then 
modelled the proportion of this combined incidence that 
was attributable to typhoid fever and the proportion 
attributable to paratyphoid fever, and split total cases 
proportionally between the two. We estimated deaths 
using an ensemble model of vital registration data for 
locations with rich vital registration data and using a 
natural history approach for other locations. For the 
natural history model, we modelled case fatality by age 
and national income category and estimated deaths 
as the product of cases and case fatality. To propagate 
uncertainty through the modelling chain, we used 
posterior simulation, estimating 1000 draws from the 
posterior distribution of each estimate, and doing all 
calculations at the draw level. The code used in this 
analysis is available online.
Incidence model
We estimated the total incidence of typhoid and para- 
typhoid fevers from hybridised estimates of two models: 
a model of moderate and high-burden super-regions 
(incidence ≥10 per 100 000) based on only incidence data; 
and a model of low-burden super-regions (incidence 
<10 per 100 000) including both incidence data and 
estimates of incidence derived from vital registration 
sources (appendix pp 5–6). Incidence data were from 
population-based cohort studies and national surveillance 
For the code used in the 
analysis see http://ghdx.
healthdata.org/gbd-2017/code
See Online for appendix
Research in context
Evidence before this study
We searched PubMed for “(“typhoid” OR “paratyphoid” OR 
“typhi” OR “paratyphi”) AND (“burden” OR “estimates” OR 
“model”)”, with no restrictions placed on date of publication or 
language. We identified global (or near-global) estimates 
of enteric fever incidence, ranging from 12 million to 
27 million cases annually. Estimates of mortality ranged 
from 129 000 to 223 000 deaths. Most previous studies assumed 
a case fatality of 1%, whereas one study estimated a case fatality 
range of 0·4% to 2·1%. Only previous iterations of the Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) have 
reported estimates of temporal trends and health gap metrics 
for typhoid and paratyphoid fevers separately. 
Added value of this study
We present estimates of the global burden of typhoid and 
paratyphoid fevers from GBD 2017, separately and collectively, 
by country, year, age, and sex. To our knowledge, this is the 
first study to provide estimates of typhoid and paratyphoid 
fever incidence, mortality, years of life lost (YLLs) to 
premature mortality, years lived with disability (YLDs), and 
disability-adjusted life-years (DALYs) at country, regional, and 
global levels, and the first study to provide global estimates of 
enteric fever trends. As such, we believe this analysis to be the 
most comprehensive picture of the burden of enteric fever to 
date. Trend estimates offer important information about the 
changing burden of the disease. Estimates of health gap metrics, 
which account for disease severity and give greater weight to 
deaths occurring at younger ages, allow for comparisons 
between diseases of differing severity and give policy makers 
the information required to set objective priorities.
Implications of all the available evidence
Growing antimicrobial resistance and national decision making 
about typhoid vaccine use heighten the need for accurate and 
detailed estimates of the global enteric fever burden. 
Our estimates, showing a decline in the number of typhoid 
and paratyphoid illnesses globally, from 25·9 million in 1990 
to 14·3 million in 2017, are similar to previously published 
estimates that have ranged from about 12 million to 27 million. 
Still, the wide uncertainty around estimates and large 
differences in region-level estimates reflect the paucity of data 
and highlight the need for more widespread active surveillance 
of enteric fever. As countries move forward with vaccine 
roll-out, better data and better surveillance should be a priority.
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systems. The systemic review, data availability maps, and 
all included sources are listed in the appendix (pp 3–4, 14, 
and 54–93). We excluded studies that reported data 
with the Widal test, given the unreliable performance 
characteristics of this diagnostic method. We assumed 
two major sources of under-reporting: first, imperfect 
blood culture sensitivity resulting in missed cases among 
those who were tested; and, second, incompleteness 
of data from passive national surveillance sources. We 
estimated blood culture sensitivity as 55% (95% CI 
39–71)17–19 and adjusted reported case estimates by 
dividing by sensitivity, using posterior simulation to 
incorporate uncertainty from the sensitivity adjustment.
We modelled incidence using the Bayesian meta-
regression tool DisMod-MR, which has been described 
elsewhere.20 DisMod-MR uses non-linear mixed-effects 
models to produce estimates by age, sex, year, and location. 
It uses age integration to accommodate data with disparate 
age categorisation schemes. Country-level covariates help 
inform estimates where data are sparse. The tool uses a 
Bayesian cascading geographical hierarchy to ensure that 
estimates have a strong spatial structure and to allow 
extrapolations to countries with no data. In addition 
to country-level covariates, DisMod accepts study-level 
covariates that allow data to be adjusted to account for 
known sources of bias and heterogeneity.
The incidence model used two country-level covariates. 
The first was the summary exposure value for unsafe 
water, which is a metric of the risk-weighted prevalence of 
exposure to unsafe water, weighted by the type of water 
supply,21 included because poor access to safe drinking 
water is a known risk factor for typhoid fever. The second 
was the proportion of the population living in the classic 
Indian Ocean monsoon belt,22 which was included both 
because typhoid fever incidence increases following 
monsoons23 and to prevent un reasonably high estimates 
in countries that have poor access to improved water 
supply  but lie outside high-incidence regions, and for 
which few data are available (primarily countries in sub-
Saharan Africa). These covariates were selected on the 
basis of disease epidemiology, the significance of their 
association with incidence (p<0·05), and non-collinearity 
(eg, sanitation was not included as a covariate because of 
its high collinearity with unsafe water). We used a study-
level covariate identifying datapoints from passive national 
surveillance systems. We indicated active surveillance as 
the reference category and allowed DisMod-MR to adjust 
reported incidence rates from passive national surveillance 
sources to their expected values under the counterfactual 
scenario that they had been recorded via active surveillance 
(see appendix p 3 for details).
Aetiology models
We estimated the aetiological breakdown of the typhoid–
paratyphoid fever envelope using data from national 
surveillance, population-based cohort studies, and vital 
registration sources (appendix pp 59–60). Although 
studies typically classify cases as being typhoid or 
paratyphoid fever, sources rarely differentiate between 
Paratyphi A, B, and C. We assume, but cannot confirm, 
that Paratyphi A is the primary paratyphoid serovar. We 
used two DisMod-MR models: one for the proportion of 
the total cases caused by typhoid fever, and a second for 
the proportion of cases caused by paratyphoid fever. We 
rescaled each proportion estimate to ensure that the 
proportions due to typhoid and paratyphoid fever always 
summed to one. For each age-sex-year-location, and for 
each draw, the incidence of typhoid fever was calculated as 
the product of total incidence and the proportion of that 
total from typhoid fever; and the incidence of paratyphoid 
fever was calcu lated as the product of the total incidence 
and proportion of that total due to paratyphoid fever.
Case fatality model
We modelled case fatality using notifiable disease and 
hospital data sources that reported both cases and deaths 
(see the appendix pp 90–93 for the full source list). We 
excluded sources that reported case fatality estimates from 
out breaks as these estimates tend to be notably higher 
than those reported under the endemic conditions in 
which most cases occur. The scarcity of case fatality data 
and the small number of sources reporting age-specific 
case fatality precluded the use of a single model to 
estimate case fatality by country, age, and year. Instead, we 
first used the age-integration abilities of DisMod-MR 
using only age-specific data to estimate a global age 
pattern. Second, we did a meta-analysis of mean all-age 
case fatality data for three income groups: high-income 
countries (World Bank “high income, OECD” and “high 
income, non-OECD” countries), upper-middle-income 
countries (equivalent to the World Bank classification), 
and low-income countries (World Bank “low-income” and 
“lower-middle income” countries).24 We then applied the 
global age pattern to the mean case fatality estimates for 
each income category to derive age-specific case fatality 
estimates for each of the three income categories. We 
estimated the relative risk of fatality among typhoid fever 
cases compared with paratyphoid fever cases using a 
single large dataset that reported case fatality separately 
for typhoid and paratyphoid fevers.25 Finally, we applied 
this relative risk to our overall case fatality estimate to 
derive separate estimates of case fatality for typhoid and 
paratyphoid fevers. As with our estimates of incidence, we 
used posterior simulation to incorporate uncertainty from 
the average case fatality, age-pattern, and the relative 
fatality of typhoid and paratyphoid fevers (see appendix 
pp 9–10 for details).
Mortality estimation
GBD uses a star-rating system from zero to five to 
represent the quality and completeness of cause of 
death (CoD) data, primarily vital registration data, for 
each location, during the GBD estimation period.26 For 
locations with four or five star CoD data (see appendix 
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Cases Deaths YLLs YLDs DALYs
Paratyphoid fever only
1990 5508 (4233–7086) 28·5 (12·7–56·7) 2071 (913–4172) 15·0 (9·4–22·6) 2086 (923–4199)
1995 5139 (3963–6543) 27·3 (12·4–53·8) 1977 (888–3912) 14·0 (8·8–21·0) 1991 (897–3931)
2000 4698 (3640–5953) 25·2 (11·5–49·9) 1817 (835–3600) 12·9 (8·1–19·5) 1830 (845–3619)
2005 4232 (3311–5327) 23·0 (10·5–45·3) 1649 (756–3259) 11·6 (7·3–17·3) 1661 (762–3274)
2010 3794 (2992–4739) 20·9 (9·5–40·6) 1477 (670–2862) 10·4 (6·7–15·5) 1487 (679–2881)
2017 3397 (2666–4184) 19·1 (8·7–37·3) 1354 (622–2620) 9·4 (5·9–13·9) 1364 (631–2641)
Typhoid fever only
1990 20 366 (17 117–23 882) 202·0 (112·5–327·1) 14 954 (8330–24 474) 192·7 (128·8–277·2) 15 147 (8493–24 777)
1995 18 424 (15 562–21 584) 185·4 (104·2–302·6) 13 693 (7658–22 281) 174·9 (117·9–254·6) 13 868 (7801–22 501)
2000 16 797 (14 229–19 550) 171·6 (96·6–278·9) 12 598 (7138–20 572) 160·0 (108·1–227·6) 12 758 (7280–20 723)
2005 15 415 (13 131–17 894) 160·2 (89·8–262·9) 11 712 (6582–19 081) 147·3 (97·6–213·2) 11 860 (6694–19 317)
2010 13 769 (11 739–15 938) 145·4 (80·9–236·0) 10 556 (5902–17 048) 132·2 (88·3–188·4) 10 688 (6028–17 188)
2017 10 924 (9343–12 597) 116·8 (65·4–187·7) 8332 (4632–13 419) 105·5 (70·3–151·0) 8437 (4731–13 577)
Typhoid and paratyphoid fevers combined
1990 25 875 (22 073–29 915) 230·5 (131·2–372·6) 17 026 (9768–27 546) 207·7(140·0–299·2) 17 233 (9931–27 789)
1995 23 563 (20 198–27 338) 212·7 (120·8–341·5) 15 671 (8845–25 182) 189·0 (127·6–273·5) 15 860 (9016–25 474)
2000 21 495 (18 521–24 788) 196·8 (113·0–315·9) 14 415 (8329–23 159) 172·8 (117·1–245·0) 14 588 (8422–23 327)
2005 19 648 (16 992–22 576) 183·2 (104·6–293·4) 13 362 (7649–21 673) 158·9 (106·0–229·1) 13 521 (7780–21 847)
2010 17 564 (15 295–20 086) 166·3 (95·2–264·5) 12 033 (6907–19 424) 142·7 (95·4–202·7) 12 175 (7033–19 654)
2017 14 321 (12 540–16 337) 135·9 (76·9–218·9) 9686 (5485–15 746) 114·9 (77·7–164·2) 9801 (5569–15 880)
95% uncertainty intervals are included in parentheses. YLL=years of life lost. YLD=years lived with disability. DALY=disability-adjusted life-years.
Table 1: Global numbers of cases, deaths, years of life lost, years lived with disability, and disability-adjusted life-years (in thousands) by year for typhoid 
and paratyphoid fevers
Figure 1: Incidence rates (per 100 000) of typhoid and paratyphoid fevers, by country, in 2017
Unfilled locations are those for which GBD does not produce estimates. The inset maps detail smaller locations. ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. GBD=Global Burden of 
Diseases, Injuries, and Risk Factors Study. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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pp 10–11 for details), we estimated deaths directly from 
vital registration data using the CoD ensemble modelling 
(CODEm) tool, which has been described elsewhere.26 
Briefly, CODEm estimates a set of plausible submodels, 
tests each for out-of-sample predictive validity, and 
produces final estimates from an ensemble derived from 
weighted combinations of submodels. For locations with 
lower than four-star CoD data, we considered the data 
insufficiently complete and used a natural history 
approach in which we estimated typhoid fever mortality 
1990 2017 Percentage change
Cases (thousands) Incidence (per 100 000) Cases (thousands) Incidence (per 100 000)
Global 25 875 (22 073 to 29 915) 439·2 (376·7 to 507·7) 14 321 (12 540 to 16 337) 197·8 (172·0 to 226·2) –54·9% (–56·5 to –53·4)
Central Europe, eastern Europe, and central Asia
Central Asia 0·1 (0·1 to 0·1) 0·2 (0·1 to 0·2) 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·1) –27·8% (–35·2 to –21·2)
Central 
Europe
1·7 (1·3 to 2·2) 1·2 (1·0 to 1·5) 1·2 (0·9 to 1·5) 0·7 (0·6 to 0·9) –41·2% (–46·1 to –35·8)
Eastern 
Europe
1·2 (0·9 to 1·5) 0·5 (0·4 to 0·6) 1·1 (0·9 to 1·5) 0·4 (0·3 to 0·5) –9·3% (–17·4 to –0·9)
High income
Australasia 0·0 (0·0 to 0·0) 0·2 (0·1 to 0·2) 0·0 (0·0 to 0·1) 0·2 (0·1 to 0·2) –4·7% (–16·2 to 7·6)
High-income 
Asia Pacific
0·9 (0·7 to 1·1) 0·5 (0·4 to 0·6) 0·7 (0·6 to 0·9) 0·3 (0·2 to 0·3) –45·4% (–52·1 to –37·9)
High-income 
North 
America
4·8 (4·1 to 5·6) 1·6 (1·3 to 1·8) 4·1 (3·2 to 5·3) 0·9 (0·7 to 1·2) –41·8% (–48·4 to –34·7)
Southern 
Latin 
America
1·6 (1·3 to 1·9) 3·2 (2·7 to 3·8) 0·5 (0·4 to 0·6) 0·7 (0·5 to 0·9) –79·2% (–82·8 to –75·1)
Western 
Europe
1·8 (1·4 to 2·2) 0·4 (0·3 to 0·5) 1·3 (1·0 to 1·6) 0·3 (0·2 to 0·4) –28·8% (–35·2 to –21·4)
Latin America and Caribbean
Andean Latin 
America
0·7 (0·6 to 1·0) 2·4 (1·8 to 3·1) 0·9 (0·7 to 1·1) 1·5 (1·2 to 2·0) –35·4% (–40·9 to –29·6)
Caribbean 3·0 (2·5 to 3·5) 8·0 (6·7 to 9·5) 2·5 (2·1 to 3·0) 5·7 (4·7 to 6·7) –29·3% (–32·4 to –26·1)
Central Latin 
America
29·7 (24·9 to 35·7) 23·1 (19·2 to 29·0) 20·0 (16·6 to 24·6) 8·2 (6·9 to 10·2) –64·3% (–67·5 to –60·5)
Tropical Latin 
America
3·8 (2·9 to 5·1) 2·8 (2·2 to 3·6) 4·3 (3·3 to 5·5) 1·9 (1·5 to 2·4) –33·2% (–38·2 to –29·4)
North Africa 
and Middle 
East
531·0 (453·5 to 615·1) 132·1 (115·2 to 150·6) 246·6 (210·8 to 286·3) 39·3 (33·7 to 45·6) –70·2% (–71·1 to –69·3)
South Asia 19 991 (16 982 to 23 298) 1506·8 (1308·4 to 1729·6) 10 286 (9002 to 11 738) 549·2 (480·7 to 625·4) –63·5% (–64·9 to –62·3)
Southeast Asia, east Asia, and Oceania
East Asia 728·4 (652·9 to 819·4) 55·6 (49·9 to 62·9) 586·6 (553·8 to 624·0) 51·0 (47·3 to 55·1) –8·3% (–16·9 to –3·6)
Oceania 29·3 (24·2 to 35·3) 381·3 (322·8 to 448·3) 20·5 (17·0 to 24·7) 144·3 (121·5 to 170·4) –62·2% (–63·6 to –60·7)
Southeast 
Asia
3028·8 (2606·1 to 3492·8) 562·0 (492·1 to 643·8) 1414·4 (1247·9 to 1592·9) 219·8 (192·9 to 249·1) –60·9% (–61·7 to –59·9)
Sub-Saharan Africa
Central 
sub-Saharan 
Africa
86·3 (69·9 to 105·8) 127·2 (108·0 to 150·8) 122·4 (100·2 to 149·1) 81·4 (68·8 to 95·8) –36·0% (–38·0 to –33·7)
Eastern 
sub-Saharan 
Africa
584·6 (489·0 to 703·5) 243·8 (210·6 to 283·6) 739·5 (627·6 to 869·7) 151·9 (132·0 to 174·6) –37·7% (–38·9 to –36·5)
Southern 
sub-Saharan 
Africa
2·2 (1·9 to 2·5) 3·5 (3·1 to 4·0) 1·9 (1·7 to 2·1) 2·3 (2·0 to 2·6) –33·9% (–35·6 to –32·3)
Western 
sub-Saharan 
Africa
843·4 (690·2 to 1027·5) 354·6 (301·7 to 418·3) 866·1 (719·7 to 1039·6) 161·1 (138·1 to 187·3) –54·5% (–55·9 to –53·2)
95% uncertainty intervals are included in parentheses. GBD regions are detailed in the appendix. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Table 2: Typhoid and paratyphoid fevers and age-standardised incidence rates by GBD region, for 1990 and 2017, and the percentage change in 
age-standardised incidence rates between 1990 and 2017
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as the product of typhoid fever incidence and case fatality. 
We estimated paratyphoid fever mortality as the product 
of paratyphoid fever incidence and case fatality. One 
funda mental principle of GBD is that the sum of all 
cause-specific mortality estimates should equal all-cause 
mortality within each age, sex, year, and location. We 
impose this consistency through CoDCorrect, a process 
in which we rescale cause-specific mortality estimates to 
fit the all-cause mortality envelope.26
Estimation of health gap metrics
We estimated three health gap metrics: YLLs, which 
quantify fatal health loss according to a reference life 
expectancy at the age of death (ie, deaths at younger ages 
result in more YLLs); YLDs, which quantify non-fatal 
health loss accounting for both the duration and severity 
of a condition; and DALYs, which are the sum of YLLs 
and YLDs, and quantify fatal and non-fatal health loss 
combined. YLLs were calculated with methods described 
previously.26
To calculate YLDs, we assigned cases proportionally 
across different sequelae, each with an associated duration 
and disability weight. We split typhoid fever cases between 
four sequelae: moderate typhoid fever, severe un complicated 
typhoid fever, severe typhoid fever with gastro intestinal 
bleeding, and severe typhoid fever with other complications 
(including, but not limited to, intes tinal perforation).27 
Paratyphoid fever cases were split between mild paratyphoid 
fever, moderate paratyphoid fever, severe paratyphoid fever, 
and paratyphoid fever with abdominal complications. Each 
sequela was assigned the disability of the most closely 
matching health state from the 235 health states in GBD 
2017.4 We assumed the duration of illness was 14 days 
(95% UI 7–21) for mild or moderate sequelae, and 28 days 
(14–49) with severe or complicated sequelae.28–31 YLDs from 
a given sequela were calculated as the product of the 
number of incident cases of that sequela, its duration in 
years, and the corresponding disability weight. Total YLDs 
for typhoid fever were calculated as the sum of the YLDs 
from each of its four sequelae, and total YLDs for 
Cases (thousands) Deaths
Typhoid fever Paratyphoid fever Percentage 
typhoid fever
Typhoid fever Paratyphoid fever Percentage 
typhoid fever
Global 10 924·3 (9343·0–12 597·1) 3396·9 (2666·5–4184·1) 76·3% (71·8–80·5) 116 815 (65 421–187 652) 19 108 (8706–37 332) 85·9% (77·7–91·9)
Central Europe, eastern Europe, and central Asia
Central Asia 0·1 (0·1–0·1) 0·0 (0·0–0·0) 81·0% (75·9–86·0) 1 (1–1) 1 (0–3) 48·9% (22·2–87·2)
Central Europe 0·1 (0·1–0·1) 1·1 (0·8–1·4) 9·3% (7·8–11·2) 2 (1–4) 1 (1–2) 62·6% (47·0–80·1)
Eastern Europe 0·6 (0·4–0·8) 0·5 (0·4–0·7) 52·7% (47·6–58·2) 1 (0–1) 1 (0–1) 41·8% (27·0–62·7)
High income
Australasia 0·0 (0·0–0·0) 0·0 (0·0–0·1) 13·3% (10·5–16·5) 0 (0–0) 0 (0–0) 39·2% (14·0–58·2)
High-income Asia Pacific 0·1 (0·1–0·1) 0·6 (0·5–0·8) 14·5% (12·6–16·6) 0 (0–1) 1 (0–2) 34·1% (18·0–73·8)
High-income North 
America
0·6 (0·4–0·8) 3·5 (2·8–4·6) 14·3% (12·6–16·3) 0 (0–1) 2 (1–7) 18·6% (6·2–30·5)
Southern Latin America 0·2 (0·1–0·3) 0·3 (0·2–0·4) 41·1% (34·6–47·6) 3 (2–6) 0 (0–0) 97·7% (92·8–99·0)
Western Europe 0·1 (0·1–0·2) 1·1 (0·9–1·4) 11·5% (9·0–14·4) 12 (7–16) 2 (0–4) 84·3% (77·1–96·4)
Latin America and Caribbean
Andean Latin America 0·9 (0·7–1·1) 0·0 (0·0–0·0) 97·8% (97·0–98·5) 7 (3–13) 0 (0–0) 98·8% (97·8–99·4)
Caribbean 0·9 (0·7–1·2) 1·6 (1·3–1·9) 37·7% (31·7–44·3) 11 (5–20) 9 (4–17) 56·3% (40·7–70·4)
Central Latin America 19·3 (16·0–23·7) 0·7 (0·6–1·0) 96·4% (95·6–97·0) 97 (59–249) 1 (1–5) 98·3% (94·3–99·6)
Tropical Latin America 4·2 (3·3–5·4) 0·1 (0·1–0·1) 97·6% (96·8–98·3) 30 (14–54) 0 (0–1) 98·7% (97·6–99·3)
North Africa and Middle East 239·4 (205·0–277·5) 7·2 (5·0–10·3) 97·1% (96·0–97·9) 2 731 (1458–4752) 43 (17–94) 98·4% (97·2–99·2)
South Asia 7478·0 (6350·9–8665·0) 2808·3 (2194·4–3478·8) 72·7% (67·4–77·7) 78 892 (44 214–125 372) 15 773 (7319–30 611) 83·4% (73·9–90·3)
Southeast Asia, east Asia, and Oceania
East Asia 378·3 (342·9–416·2) 208·3 (177·7–241·2) 64·5% (59·4–69·4) 2845 (1416–4991) 858 (361–1702) 76·9% (65·3–86·0)
Oceania 16·2 (13·3–19·5) 4·3 (3·1–5·8) 79·0% (74·0–83·6) 195 (100–350) 29 (12–60) 87·2% (79·4–92·9)
Southeast Asia 1284·6 (1132·7–1448·2) 129·8 (98·4–167·5) 90·8% (88·5–92·7) 12 090 (6822–19 869) 705 (305–1405) 94·5% (90·4–97·0)
Sub-Saharan Africa
Central sub-Saharan Africa 119·2 (97·2–145·1) 3·2 (2·1–4·6) 97·4% (96·5–98·2) 1236 (634–2188) 18 (7–41) 98·5% (97·4–99·2)
Eastern sub-Saharan Africa 726·4 (615·6–856·5) 13·1 (9·4–18·1) 98·2% (97·6–98·7) 9893 (5240–16 866) 93 (38–184) 99·1% (98·3–99·5)
Southern sub-Saharan 
Africa
1·7 (1·5–2·0) 0·1 (0·1–0·2) 92·2% (90·1–94·0) 18 (10–32) 1 (0–2) 95·5% (92·3–97·6)
Western sub-Saharan Africa 653·2 (534·8–794·0) 212·9 (158·2–278·3) 75·4% (70·2–80·0) 8751 (4481–15 514) 1568 (640–3306) 84·8% (76·2–91·4)
95% uncertainty intervals are included in parentheses. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Table 3: Breakdown of cases and deaths by cause (typhoid and paratyphoid fever) by GBD region, for 2017
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paratyphoid fever were calculated as the sum of the YLDs 
from each of its four sequelae. Finally, we adjusted YLDs 
through a comorbidity correction that ensures that 
comorbidities cannot result in an aggregate disability 
weight greater than one (equivalent to death).4
Role of the funding source
AKMZ, an employee of the funder of this study, helped 
acquire data and provided feedback and edits on the 
manuscript. The sponsor of this study had no other role 
in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
We estimate that 14·3 million (95% uncertainty interval 
[UI] 12·5–16·3) cases of typhoid and paratyphoid 
fevers occurred globally in 2017, a 44·6% (42·2–47·0) 
decline from 25·9 million (22·1–29·9) cases in 1990 
(table 1). Age-standardised incidence rates declined 
by 54·9% (53·4–56·5), from 439·2 (376·7–507·7) 
per 100 000 person-years in 1990 to 197·8 (172·0–226·2) 
per 100 000 person-years in 2017. Comparing GBD 
super-regions, south Asia had the highest age-standardised 
incidence rate (549 [481–625] cases per 100 000 person-years) 
and the largest number of cases (10·3 million [9·0–11·7]), 
accounting for 71·8% of global cases in 2017. The southeast 
Asia, east Asia, and Oceania super-region accounted for 
14·1% of global cases (2·02 million [1·82–2·23]), and the 
sub-Saharan Africa super-region accounted for 12·1% 
(1·73 million [1·45–2·06]; figure 1, table 2). Of all cases 
globally, 76·3% (71·8–80·5) were attributable to S Typhi 
(table 3). Thus, in 2017, we estimate that there were 
10·9 million (9·3–12·6) cases of typhoid fever and 
3·4 million (2.7–4·2) cases of paratyphoid fever globally 
(table 3).
Incidence rates were highest among children, peaking 
in the 5–9-year age group and declining steadily into 
adulthood (figure 2). In 2017, 12·6% (8·7–17·7) of cases 
occurred among children younger than 5 years, and 
55·9% (50·3–61·6) occurred among children younger 
than 15 years of age (appendix pp 15–16). We found 
differing age patterns in high-incidence and low-incidence 
regions, with incidence concentrated among children in 
high-incidence regions, and distributed more broadly 
across age groups in low-incidence regions (appendix 
p 17). 56·3% (51·8–61·2) of cases occurred among males.
Mean all-age global case fatality was 0·95% (0·54–1·53), 
with higher case fatality estimates among children and 
older adults, and among those living in lower-income 
countries (appendix pp 22–25). Case fatality for typhoid 
fever was 1·89 times (1·09–3·28) that for paratyphoid 
fever. Cause, age, and income-specific case fatality 
estimates for paratyphoid fever ranged from a low of 
0·3% (0·1–0·8) among adults in high-income countries 
to a high of 0·9% (0·4–1·9) among post-neonates 
(28–364 days) in lower-income countries; and those for 
typhoid fever ranged from 0·6% (0·2–1·3) among adults 
in high-income countries to 1·6% (0·8–3·0) among post-
neonates in lower-income countries (appendix p 25).
We estimated 135·9 thousand (76·9–218·9) deaths from 
typhoid and paratyphoid fever globally in 2017, a 41·0% 
(33·6–48·3) decline from 230·5 thousand (131·2–372·6) 
in 1990 (table 1). As with cases, south Asia had the highest 
mortality rates and highest absolute number of deaths, 
accounting for 69·6% (94·7 thousand [54·4–135·2]) of 
global deaths from typhoid and paratyphoid fever in 2017, 
followed by the sub-Saharan Africa super-region 
(21·6 thousand [11·3–38·1]; 15·9% of global deaths), and 
the southeast Asia, east Asia, and Oceania super-region 
(16·7 thousand [9·38–27·7]; 12·3% of global deaths; 
figure 3, appendix p 26). Mortality rates were highest 
among young children, peaking among those aged 
5–9 years, and steadily declined with age (figure 4). In 
2017, 17·2% (12·3–23·4) of deaths occurred among 
children younger than 5 years of age, and 59·3% 
(53·6–65·2%) occurred among children younger than 
15 years of age. Of all deaths globally, 85·9% (77·7–91·9) 
were attributable to S Typhi, resulting in 116·8 thousand 
(65·4–187·7) deaths from typhoid fever and 19·1 thousand 
(8·7–37·3) from paratyphoid fever in 2017 (table 3). 
74·0 thousand (42·1–120·1) deaths occurred among males 
compared with 61·9 thousand (34·7–101·4) deaths among 
females.
The 10·9 million cases of typhoid fever and 
3·4 million cases of paratyphoid fever in 2017 resulted in 
105·5 thousand (70·3–151·0) YLDs attributable to typhoid 
fever and 9·4 thousand (5·9–13·9) YLDs attributable to 
paratyphoid fever. Similarly, the 116·8 thousand deaths 
due to typhoid fever and 19·1 thousand deaths due to 
paratyphoid fever in 2017, resulted in 8·3 million 
Figure 2: Global age-specific incidence rates (per 100 000) of typhoid and 
paratyphoid fevers in 2017
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(4·6–13·4) YLLs attributable to typhoid fever and 
1·3 million (0·6–2·6) attributable to paratyphoid fever. 
Overall, typhoid and paratyphoid fever were responsible 
for 9·8 million (5·6–15·8) DALYs in 2017, down 43·0% 
(35·5–50·6) from 17·2 million (9·9–27·8) DALYs in 1990 
(table 4). In 2017, 20·5% (14·8–27·5) of DALYs occurred 
among children younger than 5 years of age, and 
67·0% (61·6–72·4) occurred among children younger 
than 15 years of age. In 2017, 5·35 million (3·01–8·59) 
DALYs occurred among males, and 4·45 million 
(2·52 –7·31) DALYs occurred among females.
Discussion
We present comprehensive global estimates of typhoid and 
paratyphoid fever by country, age, year, and sex. Our estimates 
show the number of typhoid and paratyphoid fever cases 
declining globally, from 25·9 million in 1990 to 14·3 million 
in 2017. Given the limited use of typhoid vaccine in typhoid-
endemic countries, these declines likely reflect the broad 
improvements that come with economic develop ment, 
including infrastructure improvements (eg, water supply 
and sanitation), and improved food handling practices, as 
well increased access to antibiotic treatment.
Our global estimates of cases and deaths are com- parable 
to previously published estimates (appendix p 19). Crump 
and colleagues6 estimated that, in 2000, there were 
21·7 million cases of typhoid fever (with results from a 
sensitivity analysis ranging from 10·8 million to 
43·3 million), 5·4 million cases of paratyphoid fever, and 
216 510 deaths from typhoid fever (sensitivity analysis 
range of 21 651 to 1·1 million). Buckle and colleagues,5 after 
accounting for low diagnostic sensitivity, estimated 
26·9 million (IQR 18·3–35·7) cases in 2010. Mogasale and 
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colleagues7 published two sets of estimates for low-income 
and middle-income countries for 2010: first, an estimate of 
11·9 million (95% CI 9·9–14·7) cases and 129 thousand 
(95% CI 75–208) deaths, derived from a model that 
included an adjustment for water-related risk at each study 
site; and, second, unadjusted estimates of 20·6 million 
(95% CI 17·5–24·2) cases and 223 thousand (95% CI 
131–344) deaths. Kim and colleagues11 updated the 
estimates produced by Mogasale and colleagues to include 
data from the Typhoid Fever Surveillance in Africa 
Program (TSAP), resulting in a slight upward revision to 
12·1 million (95% CI 10·0–14·8) cases from the adjusted 
model and 20·8 million (17·8–24·2) from the unadjusted 
model. Finally, Antillón and colleagues10 estimated 
17·8 million (95% CI 6·9–48·4) annual cases in low-
income and middle-income countries. Our estimates 
differ only modestly from those that have been previously 
published, and our uncertainty intervals overlap with those 
of all previous estimates, except for the estimates adjusted 
for water-related risk from Mogasale and colleagues and 
from Kim and colleagues (appendix p 19). All previous 
death estimates fall within our uncertainty intervals.
YLLs YLDs DALYs
Number (thousands) Rate (per million) Number (thousands) Rate (per million) Number (thousands) Rate (per million)
Global 9686·1 (5484·9–15 746·2) 1363·2 (770·0–2209·0) 114·88 (77·73–164·22) 15·87 (10·69–22·71) 9801 (5579–15 839) 1379·1 (784·3–2233·0)
Central Europe, eastern Europe, and central Asia
Central Asia 0·1 (0·0–0·1) 0·9 (0·4–1·5) 0·001 (0·000–0·001) 0·01 (0·01–0·01) 0·1 (0·0–0·1) 0·9 (0·4–1·5)
Central Europe 0·1 (0·0–0·1) 0·5 (0·3–0·8) 0·004 (0·003–0·006) 0·03 (0·02–0·04) 0·1 (0·1–0·1) 0·5 (0·3–0·8)
Eastern Europe 0·0 (0·0–0·0) 0·1 (0·1–0·2) 0·007 (0·004–0·011) 0·03 (0·02–0·04) 0·0 (0·0–0·1) 0·2 (0·1–0·2)
High income
Australasia 0·0 (0·0–0·0) 0·0 (0·0–0·1) 0·000 (0·000–0·000) 0·01 (0·00–0·01) 0·0 (0·0–0·0) 0·0 (0·0–0·1)
High-income 
Asia Pacific
0·0 (0·0–0·1) 0·1 (0·1–0·3) 0·003 (0·002–0·004) 0·01 (0·01–0·01) 0·0 (0·0–0·1) 0·1 (0·1–0·3)
High-income 
North America
0·1 (0·1–0·3) 0·3 (0·2–0·9) 0·016 (0·010–0·023) 0·03 (0·02–0·05) 0·1 (0·1–0·3) 0·3 (0·2–0·9)
Southern Latin 
America
0·1 (0·1–0·1) 1·2 (0·8–2·0) 0·003 (0·002–0·004) 0·04 (0·02–0·06) 0·1 (0·1–0·1) 1·2 (0·8–2·1)
Western Europe 0·2 (0·1–0·3) 0·3 (0·2–0·4) 0·005 (0·003–0·007) 0·01 (0·01–0·02) 0·2 (0·1–0·3) 0·3 (0·2–0·4)
Latin America and Caribbean
Andean Latin 
America
0·3 (0·2–0·6) 5·5 (2·7–10·5) 0·009 (0·005–0·013) 0·15 (0·09–0·22) 0·3 (0·2–0·7) 5·7 (2·9–10·6)
Caribbean 1·4 (0·7–2·5) 32·4 (15·9–60·3) 0·014 (0·009–0·020) 0·31 (0·20–0·46) 1·4 (0·7–2·5) 32·7 (16·2–60·6)
Central Latin 
America
3·7 (2·4–9·0) 15·0 (9·6–36·6) 0·19 (0·13–0·28) 0·79 (0·51–1·14) 3·9 (2·6–9·2) 15·8 (10·2–37·8)
Tropical Latin 
America
1·4 (0·7–2·6) 6·4 (3·0–11·9) 0·04 (0·03–0·06) 0·18 (0·11–0·27) 1·5 (0·7–2·6) 6·6 (3·2–12·1)
North Africa and 
Middle East
196·7 (104·3–345·6) 309·4 (164·3–544·1) 2·38 (1·56–3·48) 3·80 (2·50–5·53) 199·1 (106·6–347·6) 313·2 (167·9–547·2)
South Asia 6737·5 (3894·5–10 976·9) 3571·8 (2054·4–5791·6) 79·47 (53·40–114·18) 42·48 (28·67–60·67) 6817 (3958–11 097) 3614 (2095–5856)
Southeast Asia, east Asia, and Oceania
East Asia 237·7 (122·0–415·6) 234·4 (122·2–410·1) 4·30 (2·93–6·05) 3·70 (2·46–5·31) 242·0 (126·5–419·1) 238·1 (125·9–414·2)
Oceania 16·2 (8·3–28·7) 1082·0 (559·3–1928·3) 0·17 (0·11–0·26) 12·06 (7·69–17·84) 16·3 (8·5–28·9) 1094·1 (569·1–1942·8)
Southeast Asia 864·3 (488·9–1412·0) 1358·7 (770·0–2228·3) 12·92 (8·66–18·50) 20·07 (13·48–28·68) 877·2 (502·4–1424·3) 1378·7 (792·4–2244·9)
Sub-Saharan Africa
Central 
sub-Saharan 
Africa
93·9 (47·8–165·7) 569·7 (292·9–1007·4) 1·18 (0·75–1·75) 7·88 (5·14–11·48) 95·1 (48·7–166·8) 577·6 (300·0–1013·5)
Eastern 
sub-Saharan 
Africa
749·3 (397·3–1279·1) 1392·7 (738·9–2378·6) 7·16 (4·66–10·61) 14·71 (9·70–21·19) 756·5 (405·2–1286·6) 1407·4 (755·1–2396·0)
Southern 
sub-Saharan 
Africa
1·4 (0·7–2·5) 16·9 (8·9–30·2) 0·02 (0·01–0·03) 0·21 (0·14–0·31) 1·4 (0·8–2·5) 17·1 (9·1–30·4)
Western 
sub-Saharan 
Africa
781·7 (399·5–1408·5) 1303·3 (677·9–2307·3) 6·99 (4·42–10·39) 13·08 (8·50–19·14) 788·7 (404·6–1419·7) 1316·4 (686·4–2318·8)
95% uncertainty intervals are included in parentheses. YLL=years of life lost. YLD=years lived with disability. DALY=disability-adjusted life-years. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Table 4: Years of life lost, years lived with disability, and disability-adjusted life-years due to typhoid and paratyphoid fevers by GBD region, for 2017
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Whereas global estimates show broad agreement, 
regional estimates are more variable (appendix p 19). Our 
model suggests that incidence is highest in south Asia, 
followed by southeast Asia, western sub-Saharan Africa, 
eastern sub-Saharan Africa, and Oceania, a distribution 
that is broadly similar to that estimated by Crump and 
colleagues.6 The estimates by Mogasale and colleagues7 
and by Kim and colleagues11 suggest that incidence rates 
in central and eastern sub-Saharan Africa are similar to 
those of south Asia, but otherwise show a similar 
distribution to our estimates. Antillón and colleagues10 
suggest a notably different distribution, estimating by far 
the highest incidence rates in Oceania, followed by central 
sub-Saharan Africa, with a relatively modest incidence in 
south Asia. These differences reflect the scarce data 
available about typhoid incidence, and the resulting 
sensitivity to analytical methods. Notably, Oceania and 
central sub-Saharan Africa are two potentially high-
burden regions with almost no data, and they are the 
regions for which estimates vary most widely. Additionally, 
our estimates for Latin America and southern sub-
Saharan Africa are lower than those published previously. 
Whereas other estimates were restricted to a small 
number of older studies in these regions, we believe that 
our ability to use more recent vital registration and 
reporting data has resulted in estimates that more 
accurately reflect the burden in these regions.
Several notable strengths underlie these estimates. We 
had access to previously unavailable data, and our 
estimates are therefore based on the largest collection of 
sources yet included in a typhoid fever burden assess-
ment. Improved data access also allowed us to estimate 
case fatality by age and national income category, and to 
develop separate estimates for typhoid and paratyphoid 
fever. DisMod-MR is a powerful modelling tool that 
allowed us to use information from heterogeneous data 
and covariates, consequently allowing us to make more 
informed and detailed extrapolations over space, time, 
and age. Use of posterior simulation allowed us to 
propagate uncertainty through the modelling process. 
Finally, working within the larger GBD infrastructure 
allowed us to estimate YLLs, YLDs, and DALYs within 
the larger context of other causes of health loss, and 
thereby produce estimates that are adjusted for multiple 
causes of death and for multiple causes of non-fatal 
burden.
However, data about typhoid and paratyphoid fever are 
still relatively sparse and we have no data from much 
of sub-Saharan Africa, Oceania, and Latin America. The 
absence of data from Nigeria is a substantial source of 
uncertainty given the country’s large population and 
potentially high burden. The absence of active 
surveillance data from high-burden countries is an 
important limitation. Moreover, the degree to which 
incidence from cohort studies represents incidence 
throughout a country is questionable, as many incidence 
studies were done in urban slum areas where typhoid 
fever burden can be greatest. This suggests a need for 
data covering both a larger geographical range and a 
greater diversity of sites within countries, which might 
help reduce the biases related to site selection. Similarly, 
data about case fatality are both sparse and of questionable 
quality. No gold standard data exist for typhoid fever case 
fatality: data from passive surveillance sources are likely 
to overestimate case fatality (ie, greater under-reporting 
of less-severe and non-fatal cases than of fatalities), data 
from active surveillance sources are likely to 
underestimate case fatality (because of early diagnosis 
and treatment), and hospital-based data contain 
conflicting sources of bias (over-representation of severe 
cases would tend to produce overestimates, whereas 
diagnosis and treatment would tend to produce 
underestimates). Our method for splitting the overall 
case fatality estimates into separate estimates for typhoid 
and paratyphoid fever is also limited by the sparse data. 
That said, our case fatality estimates, ranging from 
0·3% to 1·6%, are in line with the widely held expert 
opinion that case fatality is approximately 1%,5,6 and also 
in line with estimates produced by Mogasale and 
colleagues,7 which ranged from 0·4% to 2·1%. Beyond 
data limitations, our unsafe water covariate is an 
imperfect proxy for microbiologically safe water, which 
would probably be a better measure of faecal conta- 
mination and typhoid fever risk. Moreover, our model 
does not capture the burden associated with chronic 
carriage, most notably the increased risk of gallstones 
and gallbladder cancer.32 Finally, our modelling 
framework is restricted to pre defined GBD age groups, 
which precludes estimation of burden for finer age 
categories that might be informative for vaccine policy.
Nevertheless, this study provides important information 
about the burden of typhoid and paratyphoid fevers and 
can be refined as additional data become available. 
Although SAGE has issued recommendations for typhoid 
conjugate vaccine use, decision making around vaccine 
intro duction lies largely with individual countries. Most 
countries eligible to apply for support from Gavi, the 
Vaccine Alliance, are in sub-Saharan Africa, and these 
new estimates should complement in-country 
surveillance data and offer valuable evidence to help 
countries make informed decisions around vaccine 
introduction.
Our global estimates are largely con sistent with 
previous typhoid fever burden estimates but add 
important information about the spatial distribution of 
the burden and the relative contributions of typhoid and 
paratyphoid fever; these findings offer empirical 
estimates of incidence and case fatality by age and 
income; and they provide important information about 
trends in incidence and mortality. The large differences 
in the published burden estimates for some regions 
stem from the paucity of data and highlight the need for 
more widespread active surveillance of enteric fever. As 
countries move forward with vaccine rollout, better 
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data and better surveillance must be a priority. Despite 
notable progress, typhoid and paratyphoid fevers clearly 
remain a major cause of death and disability to which 
billions of people worldwide are continuously exposed.
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